Ser131
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser131  -  syntenin (human)

Site Information
kIGLRLKsIDNGIFV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 56649728

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , esophageal cancer ( 1 ) , esophageal carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
AurA (human) ( 1 )
Kinases, in vitro:
AurA (human) ( 1 )
Treatments:
siRNA ( 1 )

Downstream Regulation
Effects of modification on syntenin:
molecular association, regulation ( 1 ) , protein stabilization ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , signaling pathway regulation ( 1 )
Induce interaction with:
EGFR (human) ( 1 ) , FAK (human) ( 1 ) , Src (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
esophageal cancer ( 1 )

References 

1

Du R, et al. (2020) SDCBP/MDA-9/syntenin phosphorylation by AURKA promotes esophageal squamous cell carcinoma progression through the EGFR-PI3K-Akt signaling pathway. Oncogene
32572158   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info